Docoh
Loading...

KNTE Kinnate Biopharma

Filed: 15 Jun 21, 4:52pm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2021



KINNATE BIOPHARMA INC.
(Exact name of Registrant as Specified in Its Charter)



Delaware001-3974382-4566526
(State or Other Jurisdiction (IRS Employer
of Incorporation)(Commission File Number)Identification No.)

3611 Valley Centre Drive, Suite 175  
San Diego, California 92130
(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 299-4699

N/A
(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class 
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.0001 par value per share KNTE 
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07Submission of Matters to a Vote of Security Holders.

Kinnate Biopharma Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2021.  The proposals voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of Two Class I Directors

 Name of Director For Withheld Broker Non-Votes
 Carl Gordon, Ph.D. 
29,918,414
 
3,461,364
 1,058,508
 Jim Tananbaum, M.D. 
30,078,195
 
3,301,583
 1,058,508

Each director nominee was duly elected to serve until the 2024 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

 For Against Abstain
 34,438,150 126 10

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 KINNATE BIOPHARMA INC.
   
Date: June 15, 2021
By:
/s/ Nima Farzan
  Nima Farzan
  Chief Executive Officer and President